2021-10-01- 2021-12-31 (second quarter)- Results after tax for the quarter amounted to -5.3 MSEK (-4.4 MSEK)
-
Revenues for the quarter amounted to 0 KSEK (67 KSEK)
-
Earnings per share for the quarter amounted to
-0,373 SEK (-0,553 SEK )*
2021-07-01- 2021-12-31 (the period, six months)- Results after tax for the period amounted to -9.3 MSEK (-7.6 MSEK)
-
Revenues for the period amounted to 0 KSEK (379 KSEK)
-
Earnings per share for the period amounted to
-0,656 SEK (-0.962 SEK )*
*During the third quarter, of the financial year 2020/2021, the Company carried out a merger of shares in the ratio 1:100, which reduced the number of shares from 789,541,300 to 7,895,413. Historical key figures per share have been recalculated with regards to the merger, which took place
CEO
"The need for modern and effective vaccines is great, not least for such a globally widespread infection as chlamydia. The end of 2021 has been an important period for the continued development of our chlamydia vaccine candidate, which of course motivates us in the continued work of developing a preventive vaccine against chlamydia infection.
Our latest preclinical study has provided us with additional data in preparation of the clinical study on our chlamydia vaccine candidate. The preclinical results show that interferon-gamma-producing CD4 T-cells have been detected after intramuscular injection, in addition to the previously confirmed antibody responses. These are very promising results, which indicate that our vaccine candidate generates an effective barrier that can prevent infection, but can also lead to more effective healing of an infection that has started. The results also take us further in the right direction and enable us to start 2022 strongly through ongoing and planned activities.
To maximize the probability of a rapid approval of our planned clinical study, we have decided to seek scientific advice from the
The preparations during 2022 for the planned clinical study will be financed by capital from the exercise of warrants of series TO 4 whose exercise period runs between
Finally, I want to give a glimpse of what fills a large part of my own time - business development. It includes two parts, partly we work long-term to prepare potential partners for the vaccine candidate against chlamydia and partly we work to expand our portfolio of innovative vaccine candidates to develop until they are attractive for licensing to larger vaccine companies. Expansion of the portfolio includes identification, evaluation and negotiation of additional vaccine candidates, and at the end of 2021 we have worked mostly with the two later steps.
As you can see, it has been a developing and important end to 2021 for
Follow us at the upcoming presentation at Aktiespararna, Aktiedagen Stockholm on 14 March and see our previous presentation,Aktiedagen Lund on 31 January."
Highlights during the period
In
In
In
In
Hans Arwidsson, Ph.D., MBA
CEO of
hans.arwidsson@eurocine-vaccines.com
+46 70 634 0171
Through its portfolio strategy, innovative vaccine candidates are given the opportunity to reach the market quicker, while investors are offered risk diversification with a big future leverage. These candidates are later licensed to partners for commercialization.
The company is in the possession of its own technology platform, Endocine(TM), which has been tested in four extensive clinical studies with over 400 subjects.
Listed at
https://news.cision.com/eurocine-vaccines/r/eurocine-vaccines-publishes-half-year-report-for-july---december-2021,c3507447
https://mb.cision.com/Main/11552/3507447/1535674.pdf
https://mb.cision.com/Public/11552/3507447/8f886df92d36ac88.pdf
(c) 2022 Cision. All rights reserved., source